Evidence map›Paper›PMID 25880415›Full record

ArticleBreast cancer research : BCR2015

FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth.

Isabelle Tancioni, Nichol L G Miller, Sean Uryu, Christine Lawson, Christine Jean, Xiao Lei Chen, Elizabeth G Kleinschmidt, David D Schlaepfer

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Mechanobiology of the Nucleolus.Biology of the cell · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Isabelle TancioniDepartment of Reproductive Medicine, University of California San Diego, Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA, 92093, USA. itancioni@ucsd.edu.
Nichol L G MillerDepartment of Reproductive Medicine, University of California San Diego, Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA, 92093, USA. nichol.miller@pfizer.com.
Sean UryuDepartment of Reproductive Medicine, University of California San Diego, Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA, 92093, USA. suryu@ucsd.edu.
Christine LawsonDepartment of Reproductive Medicine, University of California San Diego, Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA, 92093, USA. clawson@ucsd.edu.
Christine JeanDepartment of Reproductive Medicine, University of California San Diego, Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA, 92093, USA. cjean@inserm.fr.
Xiao Lei ChenDepartment of Reproductive Medicine, University of California San Diego, Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA, 92093, USA. xlc001@ucsd.edu.
Elizabeth G KleinschmidtDepartment of Reproductive Medicine, University of California San Diego, Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA, 92093, USA. ekleinsc@ucsd.edu.
David D SchlaepferDepartment of Reproductive Medicine, University of California San Diego, Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA, 92093, USA. dschlaepfer@ucsd.edu.
UC San Diego Health System · USUniversity of California San Diego · USInserm · FRPfizer (United States) · US

Funding

Role of Focal Adhesion Kinase In TumorigenesisR01CA102310 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHLAEPFER, DAVID D · 2003 to 2019
$5.0M
Signaling Connections Controlling Cell Motility and InvasionR01CA180769 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHLAEPFER, DAVID D · 2013 to 2017
$1.9M
Role of FAK in Promoting Cell MotilityR01CA087038 · NCI · SCRIPPS RESEARCH INSTITUTE · PI SCHLAEPFER, DAVID D · 2001 to 2005
$1.7M
Role of p190RhoGEF (Rgnef) in cell motility and tumor progressionF32CA159558 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MILLER, NICHOL L G · 2011 to 2013
$154k
NCI NIH HHS 1F32CA159558NCI NIH HHS CA102310NCI NIH HHS CA180769NCI NIH HHS F32 CA159558NCI NIH HHS R01 CA087038NCI NIH HHS R01 CA102310NCI NIH HHS R01 CA180769
6 · The paper itself

Abstract

introductionFocal adhesion kinase (FAK) controls cell growth and survival downstream of integrin-matrix receptors. Upon adhesion loss or FAK inhibition, FAK can translocate to the nucleus. The nucleolus is a non-membrane nuclear structure that regulates ribosome biogenesis and cell proliferation. Nucleostemin (NS), a nucleolar-localized protein, modulates cell cycle progression, stemness, and three-dimensional tumor spheroid formation. The signaling pathways that regulate NS levels in tumors remain undefined.

methodsHuman breast carcinoma cells were evaluated for growth in culture (adherent and anchorage-independent spheroid) and as orthotopic tumors. FAK signaling was evaluated by pharmacological FAK inhibitor addition (PF-271, IC50~0.1 μM) and by small hairpin RNA (shRNA) knockdown followed by re-expression of FAK wildtype (WT) or a kinase-dead (KD, K454R) FAK point mutant. Immunoblotting was used to evaluate FAK, NS, nucleolar phosphoprotein B23, and nucleolin levels. Total and phosphospecific antibody imunoblotting were used to detect changes in FAK, Akt kinase (Akt also known as protein kinase B), and 4E-binding protein 1 (4E-BP1) phosphorylation, a translation repressor protein and target of the mammalian target of rapamycin (mTOR) complex. Immunohistochemical, co-immunoprecipitation, and cellular fractionation analyses were used to evaluate FAK association with nucleoli.

resultsPharmacological (0.1 μM PF-271) or genetic inhibition of FAK activity prevents MDA-MB-231 and 4T1L breast carcinoma growth as spheroids and as orthotopic tumors. FAK inhibition triggers proteasome-mediated decreased NS levels but no changes in other nucleolar proteins such as B23 (nucleophosmin) or nucleolin. Active FAK was associated with purified nucleoli of anchorage-independent cells and present within nucleoli of human invasive ductal carcinoma tumor samples. FAK co-immunoprecipitated with B23 that binds NS and a complex between FAK, NS, Akt, and mTOR was detected. Constitutively-active Akt kinase promoted tumor spheroid growth, stabilized NS levels, and promoted pS65 4E-BP1 phosphorylation in the presence of inhibited FAK. Rapamycin lowered NS levels and inhibited pS65 4E-BP1 phosphorylation in cells with activated Akt-mTOR signaling.

conclusionsFAK signaling occurs in the nucleolus, active FAK protects NS, and Akt-mTOR pathway regulates NS protein stability needed for breast carcinoma spheroid and tumor growth.

Indexed as

AnimalsBreast NeoplasmsCell CycleCell Line, TumorCell ProliferationDisease Models, AnimalEnzyme ActivationFemaleFocal Adhesion Protein-Tyrosine KinasesGTP-Binding ProteinsHumansMiceNuclear ProteinsNucleophosminProtein Kinase InhibitorsProtein TransportFocal Adhesion Protein-Tyrosine KinasesGNL3 protein, humanGTP-Binding ProteinsNPM1 protein, humanNuclear ProteinsNucleophosminProtein Kinase InhibitorsProto-Oncogene Proteins c-aktRNA, MessengerRNA, Small InterferingSirolimus

Identifiers

PMID25880415
PMCPMC4407832
OpenAlexW2035894835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.